^
    5ms
    A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects (clinicaltrials.gov)
    P1, N=90, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AL-034
    6ms
    A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects (clinicaltrials.gov)
    P1, N=90, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial
    |
    AL-034
    almost4years
    A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Initiation date: Mar 2020 --> Jul 2020
    Clinical • Trial initiation date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Focus V (anlotinib) • AL-034
    4years
    A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Clinical • New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Focus V (anlotinib) • AL-034